

Intra vesical injection of botulinum a toxin (btx-a) in the management of painful bladder syndrome /interstitial cystitis (a ranomized control study)

Hypothesis / aims of study

With the wide spread use of BTX-A in lower urinary tract dysfunction including painful bladder syndrome and with encouraging results from some small pilot studies, we assessed the efficacy of BTX-A intravesical injection in patients with PBS/IC who did not respond to any of the conventional treatment modalities.

Study design, materials and methods

This Study started March 2008 and included 28 patients (23 women and 5 men), who were randomly divided into 2 groups: G1, 18 patients (16 women & 2 men) were injected 200U of BTX-A diluted in 20ml normal saline, while GII, 10 patients (7 women & 3 men) injected normal saline only. Submucosal injection was done under GA after cystoscopic examination & hydrodistention in both groups with video recording of the injection sites in a similar mapping in both groups. Voiding chart, the Visual Analog Scale (VAS) for pain, Cystoscopic and Urodynamic assessment were performed pre & post treatment at 1, 3 & 6 months.

Results

16 patients from G1 (88%) reported significant improvement at 1, 3 & 6 months follow up, mean VAS score significantly reduced ($p < 0.001$), decreased frequency ($p < 0.001$) with increased bladder capacity 28% at three month follow up. One patient only in GII reported subjective improvement which was non significant. No side effects detected in any patient

Interpretation of results

16 patients from G1 (88%) reported significant improvement at 1, 3 & 6 months follow up, mean VAS score significantly reduced ($p < 0.001$), decreased frequency ($p < 0.001$) with increased bladder capacity 28% at three month follow up. One patient only in GII reported subjective improvement which was non significant. No side effects detected in any patient

Concluding message

Intravesical BTX-A injection is a very effective measure in management of painful bladder syndrome/interstitial cystitis, significantly reducing bladder pain, urinary frequency and improve bladder capacity but still it is a short term management and reinjection is considered

<i>Specify source of funding or grant</i>	no fundig for this research, but institutional study
<i>Is this a clinical trial?</i>	Yes
<i>Is this study registered in a public clinical trials registry?</i>	No
<i>Is this a Randomised Controlled Trial (RCT)?</i>	Yes
<i>What were the subjects in the study?</i>	HUMAN
<i>Was this study approved by an ethics committee?</i>	Yes
<i>Specify Name of Ethics Committee</i>	Ain Shamas University Ethical Committee
<i>Was the Declaration of Helsinki followed?</i>	Yes
<i>Was informed consent obtained from the patients?</i>	Yes